GlassScriptPhysician profile
Robert G Day
NPI 1235120437
$2,364.96
in general payments reported to CMS, 2019-2025
26 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.19 · 2020: $223 · 2021: $308 · 2022: $154 · 2023: $318 · 2024: $737 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.07 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $418.50 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $304.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $234.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $171.83 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $141.43 | 2021-2025 | |
| Intuitive Surgical, INC. | $90.60 | 2024 | |
| Exact Sciences Corporation | $66.47 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $50.10 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.65 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $40.99 | 2020-2022 | |
| Verona Pharma, INC. | $34.30 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $33.38 | 2019 | |
| Abbvie INC. | $33.35 | 2023 | Vraylar |
| Amgen INC. | $32.74 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $32.25 | 2020 | |
| Amarin Pharma, INC. | $24.23 | 2021 | |
| Sumitomo Pharma America, INC. | $24.23 | 2025 | Gemtesa |
| Abbott Laboratories | $23.45 | 2024 | Freestyle Libre 3 |
| Nevro Corp. | $22.61 | 2023 | Senza |
| Cipher Pharmaceuticals US LLC | $19.15 | 2025 | Spinosad, Natroba |
| Mylan Specialty L.P. | $13.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.98 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $12.38 | 2021 | |
| Bardy Diagnostics, INC. | $8.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $7.11 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.